Compugen Announces In-Vivo Results for Two Novel Peptide Agonists of MAS GPCR for Potential Treatment of Cardiovascular Pathologies.
Business Wire › February 12, 2008
Linked as:
Extract
Compugen Announces In-Vivo Results for Two Novel Peptide Agonists of MAS GPCR for Potential Treatment of Cardiovascular Pathologies.
Peptides initially predicted using Compugen's GPCR ligand discovery engine
TEL AVIV, Israel -- Compugen Ltd. (NASDAQ:CGEN) announced today positive in-vivo results for two novel peptide agonists of the MAS G-protein coupled receptor (GPCR), indicating cardio-protective effects and therapeutic potential for the treatment of various cardiovascular and other patho...See the full content of this document
Sponsored links
